



CTI's Experience With Research Tax Credits Can Help Sponsors Save Time And Money

With [Research and Development spending in the pharmaceutical industry expected to continue to rise to an estimated \\$162 billion in the year 2020](#), pharmaceutical and biotech companies are seeking ways to find incentives to continue their valuable drug development programs. **CTI's international finance and clinical experts are able to work with our sponsors to help determine the research tax credits that may be applicable to the projects and programs in their development pipelines.**

Australia

- In partnering with CTI, sponsors may be eligible for an Australian Tax Credit of up to 43.5% of R&D activities on work performed in Australia (as of 14 July 2014).
- Credit is based on amount of spend in Australia - for companies with turnover (revenue) of less than 20 million AUD, credit can be up to 43.5% or AUD 43,500 for every AUD 100,000 spent. For companies with turnover (revenue) of greater than 20 million AUD, credit is 38.5% or AUD 38,500 for every AUD 100,000 spent.
- Note that the ultimate determination of eligibility for the credit, and the amount of the potential credit, is the responsibility of the sponsor and is dependent upon many variables of the tax situation of the sponsor.

Canada

- CTI sponsors will potentially be able to realize the benefits of the Canadian R&D credit for work performed in Canada through CTI's Canadian entities (CTI Canada is currently registered in British Columbia and Ontario, with others to potentially follow).
- R&D tax credit is available at both the federal and provincial level through the Scientific Research and Experimental Development (SR&ED) credit. 80% of contracted services are eligible for federal credit. Provincial credit rates vary by province (ex. Ontario is 10%).
- Note that the ultimate determination of eligibility for the credit, and the amount of the potential credit, is the responsibility of the sponsor and is dependent upon many variables of the tax situation of the sponsor.

Europe

- CTI's France Entity and CTI's Germany Entity received Research Tax Credit approval from the French Ministry of Research.
 - A sponsor based in France (France tax payer) can take advantage of the research tax credit by contracting with either CTI's Germany Entity or CTI's France Entity
- Subcontracted costs (such as CTI sponsor subcontracting to CTI) are eligible for research credit at an amount of 3x sponsor's own direct costs.
- Amount of credit is 50% of the eligible R&D costs in the first year, 40% in the second year and 30% thereafter.
- Note that the ultimate determination of eligibility for the credit, and the amount of the potential credit, is the responsibility of the sponsor and is dependent upon many variables of the tax situation of the sponsor.

US Orphan Drug Credit

CTI Cares Spotlight

Cincinnati Children's Hospital
Starshine Hospice and Palliative
Care Organization



When the moments with a child you love are fewer than they ought to be, StarShine is here to help make each one count.

StarShine was created to help children who are facing debilitating, life-limiting and terminal illnesses - and their families.

Nominated in honor of Mary Wersel and her family by:
Candace Gunnarson - Vice President, Health Economics and Outcomes Research & Kathy Schroeder - Vice President, Business Development Operations

[Click here for more information and to donate!](#)

- CTI's extensive work in rare and orphan disease has enabled firsthand experience in assisting our Sponsors to realize the benefits of the US Congress Orphan Drug Credit.
- This credit can be up to 50% of qualified clinical testing expenses paid or incurred in developing the drug.
- Qualifying costs occur between the date the FDA designates a drug as an "orphan drug" and the FDA's drug approval date.

With CTI's expertise and guidance, these research tax credits could mean huge cost and time savings for our sponsors, leading to more life-changing therapies in development that can reach patients around the world.

**For more information:
www.ctifacts.com
513.598.9290**

Recruiting Spotlight

Join us and work on some of the most groundbreaking clinical research, including trials in regenerative medicine, rare disease, first-in-man, transplantation, and other complex disease areas

**Clinical Research Associate
(US, Germany, France, Spain, Brazil, Australia,
Korea, Taiwan, Japan)**

- Experience in monitoring complex indications, inpatient, rare disease and oncology trials
- Our CRAs monitor Phase I through Phase IV clinical research studies with their knowledge of the drug development process, ICH/ GCP and applicable local regulations

**Manager/Director/Executive Health Outcomes
Research
(Cincinnati, OH; Raleigh, NC; Philadelphia, PA)**

- Interact with clients and multidisciplinary team to determine health outcomes/economic needs
- Design and conduct analysis of large scale databases, retrospective data analyses, clinical analyses
- Develop publications including abstracts, manuscripts, white papers, briefing documents based on analyses

**For more information and to apply:
www.ctifacts.com/careers
513.598.9290**

Upcoming Meeting Spotlight

**The Liver Meeting
American Association for the Study of Liver Diseases
(AASLD) Annual Meeting
San Francisco, CA
November 13-17, 2015**



Stop by and visit us at
Booth #118 throughout the meeting!

[Click here](#) to schedule a meeting with us while we're at AASLD!

Recent CTI Publications:

Symptoms of tuberous sclerosis complex: comparison of TSC1 versus TSC2 gene mutation

Jo Anne Nakagawa, William Irish PhD, Michael Ryan MS, Joe Womeldorff MS, Steven L. Roberds PhD

Upcoming Meetings We Will Be Attending

Stem Cell Meeting on the Mesa
La Jolla, CA - October 7 - 9

NORD Rare Disease and Orphan Product Breakthroughs Summit
Washington, DC - October 21-22

PA Life Sciences
Philadelphia, PA - October 29-30

Kidney Week - American Society for Nephrology (ASN) Annual Meeting
San Diego, CA - November 3 - 8

SoCalBIO Conference
Long Beach, CA - November 6

The Liver Meeting - American Association for the Study of Liver Diseases (AASLD) Annual Meeting
San Francisco, CA - November 13 - 17

American Society of Hematology (ASH) Annual Meeting
Orlando, FL - December 5 - 8

To schedule a meeting with us at one of these, please [click here](#)

New Additions & Promotions at CTI

Marty Budke joins as Senior Accounting Manager

Tasha Clifford joins as Senior CRA Manager

Paige Deters joins as Senior Study Coordinator

Susan Gläser joins as Clinical Trial Assistant

Tommie Grotjan promoted to Clinical Document Systems Specialist

Lynn Holmberg joins as Research Pharmacist/Assistant Study Manager

Mike Montani promoted to Senior Manager, Business Development Operations

Estelle Seka joins as Clinical Trial Assistant

Allie Schroeder promoted to Manager, Marketing & Corporate Communication

Kirsten Wellige joins as Clinical Trial Assistant

Katie Westerkamp promoted to Associate Study Manager

Join our Team!! We're looking for individuals to fill these positions:

Clinical Research Associate (US, Germany, France, Spain, Australia, Brazil, Korea, Taiwan, Japan)

Manager/Director/Executive Health Outcomes Research (Cincinnati, OH; Raleigh, NC; Philadelphia, PA)

Medical Writer (Cincinnati, OH)

Study Coordinator (Cincinnati, OH)

Study Manager (Cincinnati, OH; Raleigh, NC; Philadelphia, PA; San Francisco, CA)

[Click here for more information and to apply!](#)

This message was sent to email@example.com from:

CTI Communications | cti@ctifacts.com | CTI Clinical Trial and Consulting Services | 10123 Alliance Road | Cincinnati, OH 45242



[Unsubscribe](#)